Journal article
Improving the Cost-efficiency of Preventive Chemotherapy: Impact of New Diagnostics on Stopping Decisions for Control of Schistosomiasis
- Abstract:
- BackgroundControl of schistosomiasis (SCH) relies on the regular distribution of preventive chemotherapy (PC) over many years. For the sake of sustainable SCH control, a decision must be made at some stage to scale down or stop PC. These "stopping decisions" are based on population surveys that assess whether infection levels are sufficiently low. However, the limited sensitivity of the currently used diagnostic (Kato-Katz [KK]) to detect low-intensity infections is a concern. Therefore, the use of new, more sensitive, molecular diagnostics has been proposed.MethodsThrough statistical analysis of Schistosoma mansoni egg counts collected from Burundi and a simulation study using an established transmission model for schistosomiasis, we investigated the extent to which more sensitive diagnostics can improve decision making regarding stopping or continuing PC for the control of S. mansoni.ResultsWe found that KK-based strategies perform reasonably well for determining when to stop PC at a local scale. Use of more sensitive diagnostics leads to a marginally improved health impact (person-years lived with heavy infection) and comes at a cost of continuing PC for longer (up to around 3 years), unless the decision threshold for stopping PC is adapted upward. However, if this threshold is set too high, PC may be stopped prematurely, resulting in a rebound of infection levels and disease burden (+45% person-years of heavy infection).ConclusionsWe conclude that the potential value of more sensitive diagnostics lies more in the reduction of survey-related costs than in the direct health impact of improved parasite control.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of Record, Version of record, pdf, 665.2KB, Terms of use)
-
(Preview, Version of Record, Version of record, pdf, 440.8KB, Terms of use)
-
- Publisher copy:
- 10.1093/cid/ciae020
Authors
+ Bill & Melinda Gates Foundation
More from this funder
- Funder identifier:
- https://ror.org/0456r8d26
- Publisher:
- Oxford University Press
- Journal:
- Clinical Infectious Diseases More from this journal
- Volume:
- 78
- Issue:
- Supplement_2
- Pages:
- S153-S159
- Publication date:
- 2024-04-01
- DOI:
- ISSN:
-
1058-4838
- Pmid:
-
38662699
- Language:
-
English
- Keywords:
-
- Pubs id:
-
1992302
- Local pid:
-
pubs:1992302
- Source identifiers:
-
1942502
- Deposit date:
-
2024-07-20
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2024
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record